19946275258/15301726783
![Anti-HIF-Alpha antibody[STJ98135]](/uploads/allimg/20200927/1-20092G343015Y.jpg)
![Anti-HIF-Alpha antibody[STJ98135]](/uploads/allimg/20200927/1-20092G34301O6.jpg)
![Anti-HIF-Alpha antibody[STJ98135]](/uploads/allimg/20200927/1-20092G34301121.jpg)
![Anti-HIF-Alpha antibody[STJ98135]](/uploads/allimg/20200927/1-20092G343014c.jpg)
| Product name | Anti-HIF-Alpha antibody |
|---|---|
| Short Description | Mouse monoclonal against HIF-alpha |
| Description | Mouse monoclonal to HIF-1alpha. |
| Applications | ELISA, IF, IHC-p, WB |
| Dilution range | WB 1:500-1:2000 IHC 1:200-1:1000 IF 1:200-1:1000 ELISA 1:10000 |
| Specificity | HIF-1 alpha monoclonal antibody detects endogenous levels of HIF-1 alpha protein. |
| Protein Name | Hypoxia-Inducible Factor 1-Alpha Hif-1-Alpha Hif1-Alpha Arnt-Interacting Protein Basic-Helix-Loop-Helix-Pas Protein Mop1 Class E Basic Helix-Loop-Helix Protein 78 Bhlhe78 Member Of Pas Protein 1 Pas Domain-Containing Protein 8 |
| Immunogen | Purified recombinant fragment of human HIF-1alpha expressed in E. Coli. |
| Storage Instruction | Store at-20°C, and avoid repeat freeze-thaw cycles. |
| Note | FOR RESEARCH USE ONLY (RUO). |
| Host | Mouse |
|---|---|
| Clonality | Monoclonal |
| Clone ID | 1A3 |
| Reactivity | Human, Monkey, Mouse |
| Conjugation | Unconjugated |
| Purification | Affinity purification |
| Isotype | IgG1 |
| Formulation | Ascitic fluid containing 0.03% sodium azide, 0.5% BSA, 50% glycerol. |
| Gene ID | 3091 |
|---|---|
| Gene Symbol | HIF1A |
| Database Links | HGNC:4910 OMIM:603348 |
| Alternative Names | Anti-Hypoxia-Inducible Factor 1-Alpha antibody Anti-Hif-1-Alpha antibody Anti-Hif1-Alpha antibody Anti-Arnt-Interacting Protein antibody Anti-Basic-Helix-Loop-Helix-Pas Protein Mop1 antibody Anti-Class E Basic Helix-Loop-Helix Protein 78 antibody Anti-Bhlhe78 antibody Anti-Member Of Pas Protein 1 antibody Anti-Pas Domain-Containing Protein 8 antibody Anti-HIF1A BHLHE78 MOP1 PASD8 antibody |
| Function | Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Heterodimerizes with ARNT.heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. |
| Post-translational Modifications | S-nitrosylation of Cys-800 may be responsible for increased recruitment of p300 coactivator necessary for transcriptional activity of HIF-1 complex.; Requires phosphorylation for DNA-binding. Phosphorylation at Ser-247 by CSNK1D/CK1 represses kinase activity and impairs ARNT binding. Phosphorylation by GSK3-beta and PLK3 promote degradation by the proteasome.; Sumoylated; with SUMO1 under hypoxia. Sumoylation is enhanced through interaction with RWDD3. Both sumoylation and desumoylation seem to be involved in the regulation of its stability during hypoxia. Sumoylation can promote either its stabilization or its VHL-dependent degradation by promoting hydroxyproline-independent HIF1A-VHL complex binding, thus leading to HIF1A ubiquitination and proteasomal degradation. Desumoylation by SENP1 increases its stability amd transcriptional activity. There is a disaccord between various publications on the effect of sumoylation and desumoylation on its stability and transcriptional activity.; Acetylation of Lys-532 by ARD1 increases interaction with VHL and stimulates subsequent proteasomal degradation. Deacetylation of Lys-709 by SIRT2 increases its interaction with and hydroxylation by EGLN1 thereby inactivating HIF1A activity by inducing its proteasomal degradation.; Polyubiquitinated; in normoxia, following hydroxylation and interaction with VHL. Lys-532 appears to be the principal site of ubiquitination. Clioquinol, the Cu/Zn-chelator, inhibits ubiquitination through preventing hydroxylation at Asn-803. Ubiquitinated by a CUL2-based E3 ligase.; In normoxia, is hydroxylated on Pro-402 and Pro-564 in the oxygen-dependent degradation domain (ODD) by EGLN1/PHD2 and EGLN2/PHD1. EGLN3/PHD3 has also been shown to hydroxylate Pro-564. The hydroxylated prolines promote interaction with VHL, initiating rapid ubiquitination and subsequent proteasomal degradation. Deubiquitinated by USP20. Under hypoxia, proline hydroxylation is impaired and ubiquitination is attenuated, resulting in stabilization. In normoxia, is hydroxylated on Asn-803 by HIF1AN, thus abrogating interaction with CREBBP and EP300 and preventing transcriptional activation. This hydroxylation is inhibited by the Cu/Zn-chelator, Clioquinol. Repressed by iron ion, via Fe(2+) prolyl hydroxylase (PHD) enzymes-mediated hydroxylation and subsequent proteasomal degradation.; The iron and 2-oxoglutarate dependent 3-hydroxylation of asparagine is (S) stereospecific within HIF CTAD domains. |
| Cellular Localization | Cytoplasm Nucleus Nucleus Speckle Colocalizes With Hif3a In The Nucleus And Speckles (By Similarity) Cytoplasmic In Normoxia Nuclear Translocation In Response To Hypoxia |
| Tissue Specificity | Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors. A higher level expression seen in pituitary tumors as compared to the pituitary gland. |
| Swiss-Prot Key | HIF1A_HUMAN |
![Anti-COX4 antibody[STJ97368]](/uploads/thumb/350_350/1-20092Q35Z0A5.jpeg)
![Anti-Bcl-2 antibody[STJ96943]](/uploads/thumb/350_350/1-200925094RMD.jpeg)
